GTCR and Carlyle Group are buying Albany Molecular Research for $922 million

GTCR and Carlyle Group are buying Albany Molecular Research for $922 million


Contract drug manufacturer and research company Albany Molecular Research Inc said on Tuesday it agreed to be taken private by buyout firms Carlyle Group LP and GTCR LLC for about $922 million in cash. Albany Molecular's stockholders will receive $21.75 for each share they hold, representing a premium of about 10 percent to the stock's Monday close.



from Biotech News